The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer

European Journal of Cancer

Volumn 68, Issue , 2016, Pages 11-21

  Abdel Qadir, Husam ^a,b,c,d   Amir, Eitan ^a,c,e   Fischer, Hadas D ^b   Fu, Longdi ^b   Austin, Peter C ^b,c   Harvey, Paula J ^a,d,f,g   Rochon, Paula A ^a,b,c,d,f   Lee, Douglas S ^a,b,c,g   Anderson, Geoffrey M ^b,c,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Anastrozole; Cardio oncology; Coronary artery disease; Endocrine therapy; Exemestane; Hormonal therapy; Letrozole; Survivorship

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR RISK; COHORT ANALYSIS; EARLY CANCER; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MEDICAL HISTORY; OBSERVATIONAL STUDY; ONTARIO; POPULATION RESEARCH; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY ANALYSIS; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; COMPARATIVE STUDY; INFORMATION RETRIEVAL; MYOCARDIAL INFARCTION; PATHOLOGY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; INFORMATION STORAGE AND RETRIEVAL; LOGISTIC MODELS; MYOCARDIAL INFARCTION; NEOPLASM STAGING; ONTARIO; POSTMENOPAUSE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; TAMOXIFEN;

EID: 84989171888     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.08.022     Document Type: Article

References (43)

1. [1] Renehan, A.G., Tyson, M., Egger, M., Heller, R.F., Zwahlen, M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:9612 (2008 Feb 16), 569–578.
2. [2] Stoll, B.A., Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr 53:2 (1999 Feb), 83–87.
3. [3] Key, T.J., Appleby, P.N., Reeves, G.K., Roddam, A., Dorgan, J.F., Longcope, C., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:16 (2003 Aug 20), 1218–1226.
4. [4] Calle, E.E., Kaaks, R., Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:8 (2004 Aug), 579–591.
5. [5] Reeves, G.K., Pirie, K., Beral, V., Green, J., Spencer, E., Bull, D., Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ, 335(7630), 2007 Dec 1, 1134.
6. [6] Canoy, D., Cairns, B.J., Balkwill, A., Wright, F.L., Green, J., Reeves, G., et al. Body mass index and incident coronary heart disease in women: a population-based prospective study. BMC Med, 11, 2013, 87.
7. [7] Jones, L.W., Haykowsky, M.J., Swartz, J.J., Douglas, P.S., Mackey, J.R., Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50:15 (2007 Oct 9), 1435–1441.
8. [8] Patnaik, J.L., Byers, T., DiGuiseppi, C., Dabelea, D., Denberg, T.D., Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res, 13(3), 2011, R64.
9. [9] Yancik, R., Wesley, M.N., Ries, L.A., Havlik, R.J., Edwards, B.K., Yates, J.W., Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:7 (2001 Feb 21), 885–892.
10. [10] Plana, J.C., Galderisi, M., Barac, A., Ewer, M.S., Ky, B., Scherrer-Crosbie, M., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:9 (2014 Sep), 911–939.
11. [11] Yeh, E.T., Bickford, C.L., Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:24 (2009 Jun 16), 2231–2247.
12. [12] Vejpongsa, P., Yeh, E.T., Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64:9 (2014 Sep 2), 938–945.
13. [13] Jaworski, C., Mariani, J.A., Wheeler, G., Kaye, D.M., Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61:23 (2013 Jun 11), 2319–2328.
14. [14] Lal, H., Kolaja, K.L., Force, T., Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol 61:3 (2013 Jan 22), 267–274.
15. [15] Burstein, H.J., Temin, S., Anderson, H., Buchholz, T.A., Davidson, N.E., Gelmon, K.E., et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:21 (2014 Jul 20), 2255–2269, 10.1200/JCO.2013.54.2258 Epub 2014 May 27. PubMed PMID: 24868023; PubMed Central PMCID: PMC4876310.
16. [16] Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:3 (2010 Jan 20), 509–518.
17. [17] Mayer, E.L., Burstein, H.J., Postmenopausal breast cancer: a best endocrine strategy?. Lancet 386:10001 (2015 Oct 3), 1317–1319, 10.1016/S0140-6736(15)61206-5 Epub 2015 Jul 23. PubMed PMID: 26211823.
18. [18] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Dowsett, M., Forbes, J.F., Bradley, R., Ingle, J., Aihara, T., Bliss, J., et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386:10001 (2015 Oct 3), 1341–1352, 10.1016/S0140-6736(15)61074-1 Epub 2015 Jul 23. PubMed PMID: 26211827.
19. [19] Tannock, I.F., 10-year analysis of the ATAC trial: wrong conclusion?. Lancet Oncol 12:3 (2011 Mar), 216–217.
20. [20] Amir, E., Seruga, B., Niraula, S., Carlsson, L., Ocana, A., Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:17 (2011 Sep 7), 1299–1309.
21. [21] United States Food and Drug Administration, Anastrozole: full prescribing information. 2012.
22. [22] Robles, S.C., Marrett, L.D., Clarke, E.A., Risch, H.A., An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol 41:5 (1988), 495–501.
23. [23] Walters, S., Maringe, C., Butler, J., Brierley, J.D., Rachet, B., Coleman, M.P., Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership. Int J Cancer 132:3 (2013 Feb 1), 676–685.
24. [24] Levy, A.R., O'Brien, B.J., Sellors, C., Grootendorst, P., Willison, D., Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol 10:2 (2003), 67–71.
25. [25] Hux, J.E., Ivis, F., Flintoft, V., Bica, A., Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25:3 (2002 Mar), 512–516.
26. [26] Schultz, S.E., Rothwell, D.M., Chen, Z., Tu, K., Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33:3 (2013 Jun), 160–166.
27. [27] Tu, K., Mitiku, T., Lee, D.S., Guo, H., Tu, J.V., Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD). Can J Cardiol 26:7 (2010 Aug), e225–e228.
28. [28] Tu, K., Campbell, N.R., Chen, Z.L., Cauch-Dudek, K.J., McAlister, F.A., Accuracy of administrative databases in identifying patients with hypertension. Open Med 1:1 (2007), e18–e26.
29. [29] Alter, D.A., Naylor, C.D., Austin, P., Tu, J.V., Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 341:18 (1999 Oct 28), 1359–1367.
30. [30] Austin, P.C., Lee, D.S., Fine, J.P., Introduction to the analysis of survival data in the presence of competing risks. Circulation 133:6 (2016 Feb 9), 601–609.
31. [31] Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:3 (2011 May), 399–424.
32. [32] Austin, P.C., Stuart, E.A., Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:28 (2015 Dec 10), 3661–3679.
33. [33] Austin, P.C., The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32:16 (2013 Jul 20), 2837–2849.
34. [34] Riggs, B.L., Hartmann, L.C., Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med 348:7 (2003 Feb 13), 618–629.
35. [35] Maffei, L., Murata, Y., Rochira, V., Tubert, G., Aranda, C., Vazquez, M., et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89:1 (2004 Jan), 61–70.
36. [36] Burstein, H.J., Prestrud, A.A., Seidenfeld, J., Anderson, H., Buchholz, T.A., Davidson, N.E., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:23 (2010 Aug 10), 3784–3796.
37. [37] Sierra-Ramirez, A., Morato, T., Campos, R., Rubio, I., Calzada, C., Méndez, E., et al. Acute effects of testosterone on intracellular Ca2+ kinetics in rat coronary endothelial cells are exerted via aromatization to estrogens. Am J Physiol Heart Circ Physiol 287:1 (2004 Jul), H63–H71.
38. [38] Diano, S., Horvath, T.L., Mor, G., Register, T., Adams, M., Harada, N., et al. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 6:1 (1999), 21–28.
39. [39] Lew, R., Komesaroff, P., Williams, M., Dawood, T., Sudhir, K., Endogenous estrogens influence endothelial function in young men. Circ Res 93:11 (2003 Nov 28), 1127–1133.
40. [40] Hayashi, T., Esaki, T., Muto, E., Kano, H., Asai, Y., Thakur, N.K., et al. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol 20:3 (2000 Mar), 782–792.
41. [41] Mukherjee, T.K., Dinh, H., Chaudhuri, G., Nathan, L., Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 99:6 (2002 Mar 19), 4055–4060.
42. [42] Mouridsen, H., Keshaviah, A., Coates, A.S., Rabaglio, M., Castiglione-Gertsch, M., Sun, Z., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 25:36 (2007 Dec 20), 5715–5722.
43. [43] Chlebowski, R.T., Haque, R., Hedlin, H., Col, N., Paskett, E., Manson, J.E., et al. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat 154:3 (2015 Dec), 609–616.